Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MSK II Test 2 > Intro to Agents that Act on the NMJ > Flashcards

Intro to Agents that Act on the NMJ Flashcards

1
Q

What are the NTs involved in the peripheral nervous system?

A

AcH, acting on nicotinic R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the steps involved in NMJ neurotransmission?

A

1)Axonal conduction

2)Junctional transmission (cholinergic) (process is prototype for neurotransmission)

1) Synthesis of acetylcholine (ACh)
2) Storage of ACh
3) Release of ACh
4) Destruction of ACh

3)ACh signaling

4)Muscle contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is involved with junctional transmission at the NMJ?

A

1) ACh synthesis - AcCoA + choline, via ChAT
2) ACh storage - via transporter into vesicle
3) ACh release - via interaction with vesicular VAMPS and membrane SNAPS
4) ACh destruction - via AChesterase on target cell membrane, or auto-downregulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the characteristics of neuromuscular blockers of skeletal muscle relaxants?

A
  • Lack CNS activity
  • Interfere with transmission at the neuromuscular end plate
  • Used as adjuncts during anesthesia
  • No known effects on pain threshold or consciousness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the characteristics of the spasmolytic agents that are skeletal mm relaxants?

A
  • Often called centrally acting muscle relaxants
  • Used to reduce spasticity in a variety of neurologic conditions (chronic back pain, fibromyalgia, muscle spasms)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How can neuromuscular blocking agents (NMBAs) be classified?

A

Can be classified in three ways:

  1. Type of blockade (mechanism of action) - Depolarizing, Nondepolarizing
  2. Pharmacokinetic properties - Time of onset, duration of action, mode of elimination
  3. Chemical structure - Most bear resemblance to ACh
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the MOA for nondepolarizing blockade neuromuscular blocking agents?

A
  • Prevent access of ACh to the nACh receptor (competitive antagonism) and block depolarization
  • Prototype: d-tubocurarine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the MOA for depolarizing blockade neuromuscular blocking agents?

A
  • Neuromuscular blockade that results from excess of a depolarizing agonist (receptor desensitization)
  • Prototype: succinylcholine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is curare?

A

•Curare is a common name for various dart poisons originating from dozens of plants found in Central and South America

  • prototypical non-depolarizing NMBA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the MOA for curare?

A

•MOA: competitive antagonists at both pre- and post-junctional nACh receptors

Interferes with ACh mobilization at the nerve ending

Prevents membrane depolarization and muscle contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the general rule for nondepolarizing NMBAs?

A

General Rule: larger muscles are more resistant to blockade and recover more rapidly

Clearance, duration of action, and time to onset/potency varies within this class of drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the clinically useful depolarizing NMBA?

A

succinylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the duration of action for succinylcholine?

A
  • Ultra-short duration of action is due to rapid hydrolysis and inactivation by butyrylcholinesterase (aka, pseudocholinesterase or plasma cholinesterase)
  • Not effectively metabolized at the NMJ by acetylcholinesterase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the MOA for succinylcholine?

A
  1. Phase 1 depolarizing block
  2. Phase 2 desensitizing block
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is a phase I: depolarizing block?

A
  • Mimics the effects of endogenous ACh, but duration of action is longer
  • Depolarized membranes remain depolarized and unresponsive to subsequent impulses
  • Fasciculations may occur due to depolarization spread to adjacent myocytes
  • Flaccid paralysis results due to lack of repolarization
  • Enhanced by cholinesterase inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is phase 2: desensitizing block?

A
  • Membrane becomes repolarized
  • Desensitized receptors cannot be depolarized again
  • nAChR behaves as if in a prolonged closed state (similar behavior to nondepolarizing block)
  • Antagonized by AChE inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is an important distinguishing property of NMBAs?

How are they administered?

Do they penetrate the CNS?

A

Time of onset is an important distinguishing property

Limited CNS penetration

Parenteral administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the ultrashort acting NMBAs? What is the time of onset and duration of action?

A

succinylcholine

onset: 1-1.8 min., duration 5-8 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the intermediate acting NMBAs? What is the time of onset and duration of action?

A

atracurium: 2-3 min onset, 20-35 min duration
cisatracurium: 2-3 min onset, 24-45 min duration
rocuronium: 1-2 min onset, 20-35 min duration
vecuronium: 2-4 min onset, 20-35 min duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the lopng acting NMBAs? What is the time of onset and duration of action?

A

doxacurium: 4-8 min onset, 90-120 min duration
pancuronium: 3-4 min onset, 60-100 min duration
pipecuronium: 2-6 min onset, 30-90 min duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the clinical indications for NMBAs?

A
  • Surgical relaxation
  • Endotracheal intubation
  • Control of ventilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What dictates choice of NMBA agent?

A
  • Pharmacokinetics dictate choice of agent:
  • Rapid time of onset for rapid sequence intubation
  • Succinylcholine, rocuronium, vecuronium
  • Longer duration of action for surgical muscle relaxation
  • Pancuronium, atracurium, cisatracurium
  • Hepatic and/or renal insufficiency
  • Atracurium, cisatracurium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the ADRs of nondepolarizing NMBAs?

A
  • Stimulation of histamine release
  • Bronchospasm, hypotension, bronchial and salivary secretion
  • Can be alleviated by premedication with antihistamines
  • Steroids cause the least histamine release; also minimal release with atracurium and cisatracurium
  • Cardiovascular effects
  • Profound hypotension and tachycardia
  • Effects are variable within the class
  • d-Tubocurarine is not used clinically due to severe AEs and long duration of action
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the ADRs of succinylcholine?

A
  • Hyperkalemia
  • Most common AE, severe in patients with burns, nerve damage or neuromuscular damage, head trauma, or other injuries
  • Cardiovascular effects - negative inotropic and chronotropic
  • Increased intraocular pressure
  • Increased gastric pressure
  • Muscle pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the CIs to succinylcholine?

A
  • Personal or familial history of malignant hyperthermia
  • Skeletal myopathies
  • Acute phase of injury following major burns
  • Cardiac arrest risk in apparently healthy children subsequently found to have undiagnosed skeletal muscle myopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What are some clinical interactions to consider with NMBAs?

A
  • Aging: renal and hepatic function
  • Disease - Myasthenia gravis, severe burns and other neurologic injuries
27
Q

What are some drug-drug interactions to consider with NMBAs?

A
  • Drug-drug interactions
  • Some agents enhance the neuromuscular blocking effects
  • Aminoglycosides, inhaled general anesthetics, local anesthetics
  • Other agents diminish the neuromuscular blocking effects
  • Loop diuretics (high doses), phenytoin
28
Q

How is a neuromuscular blockade reversed?

A

•Theoretically, administration of an agonist would work

  • Examples: ACh, succinylcholine
  • Rapidly degraded; succinylcholine ultimately induces paralysis

•In practice, cholinesterase inhibitors are used

•Examples: neostigmine, pyridostigmine, edrophonium

MOA: antagonize nondepolarizing blockade by increasing amount of ACh at NMJ

29
Q

In addition to AChE inhibitors, what other drugs are used to reverse a neuromuscular blockade?

A
  • Antimuscarinics are often used as adjuncts to AChE Inhibitors
  • Examples: atropine, glycopyrrolate
  • MOA: block peripheral effects of ACh saturation at parasympathetic synapses (salivation, bradycardia, bronchoconstriction, nausea, vomiting mediated by muscarinic ACh recptors)
30
Q

What are the limitations of cholinesterase inhibitors?

A
  • Ineffective in reversing deep neuromuscular blockade
  • Slow onset of action
  • Unpredictable efficacy
  • Residual blockade in large number of patients
31
Q

What is the MOA for sugammadex? ADRs?

A

sugammadex - Bridion

  • MOA: binds rocuronium and vecuronium in plasma, creating a concentration gradient away from the NMJ
  • FDA approved in December 2015 for reversal of neuromuscular blockade induced by rocuronium or vecuronium
  • Adverse effects include rare, but potentially dangerous hypersensitivity reactions
  • May reduce the efficacy or oral and non-oral progestin-containing contraceptives
32
Q

What are some non-centrally acting spasmolytic agents? How effective are current spasmolytics?

A

•Current spasmolytics provide relief from the discomfort and pain of muscle spasms but infrequently allow a return to normalcy

Dantrolene

Botulinum toxin

33
Q

What is the MOA of dantrolene? Clinical uses?

A

Dantrolene

  • MOA: inhibits ryanodine receptors in the sarcoplamic reticulum and blocks release of Ca2+
  • Used in treatment of malignant hyperthermia
34
Q

What is the MOA of botulinum toxin? What are the clinical uses?

A

Botulinum toxin

  • MOA: cleaves the SNARE complex and blocks docking/fusion to the presynaptic membrane, inhibiting ACh release
  • Useful for generalized spastic disorders
35
Q

What do cholinomimetics do?

A

Mimic the actions of ACh on nicotinic and muscarinic ACh receptors

36
Q

Where are muscarinic ACh receptors?

A

nerves

heart and smooth mm

glands and endothelium

37
Q

Where are nicotinic ACh receptors?

A

neuromuscular end plate, skeletal mm

autonomic ganglion cells

38
Q

How is ACh recycled?

A
  • Acetylcholinesterase (AChE): enzyme that cleaves ACh into choline and acetate
  • Choline is recycled back into the motor neuron via the choline transporter
  • Endocytosis occurs at the nerve terminal to replenish the number of available vesicles
39
Q

What is the fxn of cholinesterases?

A

•Function: split ACh into acetic acid and choline

40
Q

What are the 2 types of cholinesterases?

A

butyrylcholinesterase

acetylcholinesterase

41
Q

What is butyrylcholinesterase?

A
  • Butyrylcholinesterase (pseudocholinesterase, BuChE)
  • Plasma and liver
  • Succinylcholine and mivacurium
42
Q

What is acetylcholinesterase? What is it targeted by?

A
  • Acetylcholinesterase (AChE)
  • Found in cholinergic synapses and neurons
  • Primary target for AChE inhibitors
  • Inhibition of AChE causes diffuse effects throughout the body
43
Q

What are the chemical classes of AChE inhibitors?

A
  • Three chemical groups
  • Alcohols – charged, reversible
  • Carbamates – charged or uncharged, reversible
  • Organophosphates – mostly uncharged, irreversible, highly lipid soluble
44
Q

What is the chemical grouping of AChE inhibitors important?

A
  • Chemistry dictates PK profile
  • Charged vs. uncharged
  • Lipid soluble or insoluble
  • Reversible or irreversible binding
45
Q

What is an alcohol AChE inhibitor? What is its lipid solubility? Charged or uncharged?

A

Edrophonium

duration: 5-15 min

lipid solubility - low

charged

46
Q

What are the properties of charged AChE inhibitors?

A
  • Insoluble in lipids
  • Do not cross the blood-brain barrier
  • Poor PO absorption
47
Q

What are some carbamate AChE inhibitors? What is the lipid solubility? Charged or uncharged?

A

neostigmine: duration 0.5 - 2 hours, low lipid solubility, charged
pyridostigmine: duration 3-6 hours, low lipid solubility, charged
physostigmine: duration 0.5 - 2 hours, high lipid solubility, uncharged

48
Q

What are the characteristics of uncharged AChE inhibitors?

A
  • Lipid soluble
  • Cross the BBB
  • Readily absorbed
49
Q

What is an organophosphate AChE inhibitor? What is its lipid solubility? Charged or uncharged?

A

echothiophate: 100 hr duration, low lipid solubility, charged

*Echotiophate is an unusual organophosphate. Most organophosphates are uncharged and highly lipid soluble, making them easy to absorb via multiple routes and also extremely toxic. Echotiophate is the only clinically useful organophosphate.

50
Q

What are the uses of AChE inhibitors?

A
  • Myasthenia gravis
  • Reversal of neuromuscular blockade during anesthesia
  • Dementia associated with Alzheimer or Parkinson disease
  • Antidote for anticholinergic poisoning - Symptoms reflect sympathetic nervous system activation (fight or flight)
  • Poisoning due to organophosphate pesticide exposure
  • Pretreatment of Soman nerve gas exposure
  • High concentrations of long-acting agents are used as chemical warfare (e.g., soman gas)
51
Q

What are the pharmacodynamics of AChE inhibitors?

A
  • Bind to AChE (also BuChE) and block its enzymatic activity
  • Increase the concentration of ACh at the NMJ
  • Stimulates both nAChRs and mAChRs
  • Consequences can be therapeutic or deadly (organophosphates, others at high concentrations)
52
Q

What are the pharmacodynamics affecting AChE inhibitors?

A

Cholinesterase inhibitors have the potential to produce the following effects dependent on their distribution (and other factors):

  1. Stimulation of mAChRs at autonomic effector organs (smooth muscle)
  2. Stimulation, followed by depression or paralysis, of all autonomic ganglia (NNAChRs) and skeletal muscle (NMAChRs)
  3. Stimulation, with occasional subsequent depression, of cholinergic receptor sites in the CNS (NNAChRs)
53
Q

What is the end-organ effect of AChE inhibitors on the CNS?

A
  • Therapeutic concentrations
  • Diffuse activation of electroencephalogram
  • Subjective altering response
  • Toxic concentrations
  • Hyperstimulation of neurons
  • General convulsions
  • Coma
  • Respiratory arrest
54
Q

What are the end-organ effects of AChE inhibitors on the NMJ?

A
  • Increased strength of contraction at low concentrations
  • Paralysis at high concentrations (succinylcholine-like)
55
Q

What is the effect of AChE inhibitors in the periphery?

A

mAChR stimulation:

eye:

sphincter mm of iris - contraction (miosis)

ciliary mm - contraction for near vision

lung:

bronchial mm - contraction/bronchoconstriction

bronchial glands - stimulation

GI tract

increased motility, relaxed sphincters, stimulated secretion

urinary bladder:

detrussor mm - contraction

trigone and sphincter mm - relaxation

Glands:

increased secretion from sweat, salivary, lacrimal, nasopharyngeal

56
Q

What are the CV system effects of AChE inhibitors?

A
  • Increase in the activity of both sympathetic and parasympathetic ganglia (nAChRs)
  • Parasympathetic tone dominates at tissue level (M2 AChRs)
  • Cardiac output falls
  • Bradycardia
  • Decreased atrial contractility
  • Reduction in ventricular contractility
  • Toxic concentrations
  • Marked bradycardia
  • Hypotension
57
Q

What are the signs of acute AChE inhibitors toxicity? How does route matter?

A
  • Acute intoxication (parasympathetic effects): SLUDGE
  • Salivation, Lacrimation, Urination, Defecation, Gastrointestinal, Emesis
  • Ingestion: GI symptoms occur first
  • Percutaneous absorption: localized sweating and muscle fasciculations
  • Lipid-soluble agents: CNS involvement follows rapidly
58
Q

What are some consequences of parasym tone?

A
  • Cholinergic
  • Salivation, lacrimation
  • Pupil constriction (myosis)
  • Decrease in HR
  • Increased secretion and motility
  • Urination, defecation
59
Q

What are some consequences of sympathetic tone?

A
  • Adrenergic (anticholinergic)
  • Cutaneous vasodilation
  • Pupil dilation (mydriasis)
  • Increase in HR
  • Decreased secretion and motility
  • Reduction/elimination of the desire to urinate
60
Q

What effects are generally seen from SNS/PNS tone?

A

Effects are generally, but not always, opposite

ØRest and digest

ØSmooth muscle contraction

ØBlocked by atropine

  • versus -

ØFight or flight

ØSmooth muscle relaxation

ØReversed by acetylcholinesterase inhibitors

61
Q

How is AChE inhibitor poisoning treated and diagnosed?

A
  • Use history of exposure and characteristic symptoms
  • Measurement of AChE activity in erythrocytes and plasma
  • Treatment includes the following:
  1. Atropine: antidote for cholinergic poisoning (mAChR antagonist)
  2. Maintenance of vital signs (particularly respiration)
  3. Decontamination

•What about nAChR stimulation?

62
Q

What is the MOA for cholinesterase regeneratoris? Prototype?

A
  • MOA: Re-activate inactive AChE by removing the phosphorous group from the active site
  • Can restore active enzyme within minutes
  • Must give before aging occurs
  • Prototype: pralidoxime
63
Q

What is the current antidote for organophosphate exposure?

A
  1. Parenteral atropine
  2. Oxime (pralidoxime)
  3. Benzodiazepine to alleviate convulsions
64
Q
A

MSK II Test 2 (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions